These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7953047)

  • 1. High-dose antipsychotic medication.
    Will D; Wrate RM; Bhate S; Taylor P; James T; Rothery D; Clark A
    Br J Psychiatry; 1994 Aug; 165(2):269-70. PubMed ID: 7953047
    [No Abstract]   [Full Text] [Related]  

  • 2. Risperidone in adolescents.
    Cozza SJ; Edison DL
    J Am Acad Child Adolesc Psychiatry; 1994 Oct; 33(8):1211. PubMed ID: 7527022
    [No Abstract]   [Full Text] [Related]  

  • 3. [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro].
    Lambert M; Correll C
    Nervenarzt; 2015 Nov; 86(11):1420-3. PubMed ID: 26542155
    [No Abstract]   [Full Text] [Related]  

  • 4. [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Con].
    Bechdolf A; Laier S; Kallenbach M; Biester A; Leopold K
    Nervenarzt; 2015 Nov; 86(11):1424-6. PubMed ID: 26542156
    [No Abstract]   [Full Text] [Related]  

  • 5. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 6. [Atypical antipsychotic agents in the adolescent: what implications for the future?].
    Cohen D
    Encephale; 2011 Sep; 37(4 Suppl 4):H15-7. PubMed ID: 22108183
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased vomiting among patients treated with neuroleptics.
    Thornton JF; Hudson C; Cavner G
    Schizophr Res; 1992 Jul; 7(2):197. PubMed ID: 1355357
    [No Abstract]   [Full Text] [Related]  

  • 8. [Depot antipsychotics in the year 2011].
    Knegtering H; Oolders H; Ruijsink MA; van der Moolen AE
    Tijdschr Psychiatr; 2011; 53(2):95-105. PubMed ID: 21319066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment challenges in the acute hospital setting.
    Kasper S
    World J Biol Psychiatry; 2005; 6(4):210-1. PubMed ID: 16272076
    [No Abstract]   [Full Text] [Related]  

  • 10. High-dose antipsychotic medication.
    Abrahamson D
    Br J Psychiatry; 1994 Aug; 165(2):269. PubMed ID: 7953046
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-life dosing with second-generation antipsychotics.
    Correll CU
    J Clin Psychiatry; 2005 Dec; 66(12):1610-1. PubMed ID: 16401165
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuroleptic dose reduction in persistently psychotic patients.
    Faraone SV; Green AI; Brown W; Yin P; Tsuang MT
    Hosp Community Psychiatry; 1989 Nov; 40(11):1193-5. PubMed ID: 2572532
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
    Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
    Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study].
    Romain JL; Dermain P; Greslé P; Grignon S; Moisan P; Nore D; Pech G; Benyaya J; Perret I
    Encephale; 1996; 22(4):280-6. PubMed ID: 9035983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
    Citrome L; Jaffe A; Levine J
    Am J Psychiatry; 2005 Mar; 162(3):631; author reply 632-3. PubMed ID: 15741497
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of betaxolol in neuroleptic-induced akathisia.
    Adler LA; Angrist B; Rotrosen J
    Psychiatry Res; 1991 Nov; 39(2):193-8. PubMed ID: 1686812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
    Leblanc G; Cormier H; Gagné MA; Vaillancourt S
    Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.